Maternofetal consequences of Coxiella burnetii infection in pregnancy: a case series of two outbreaks by Katharina Boden et al.
RESEARCH ARTICLE Open Access
Maternofetal consequences of Coxiella burnetii
infection in pregnancy: a case series of two
outbreaks
Katharina Boden1*, Andreas Brueckmann2, Christiane Wagner-Wiening3, Beate Hermann4, Klaus Henning5,
Thomas Junghanss6, Thomas Seidel7, Michael Baier4, Eberhard Straube4 and Dirk Theegarten8
Abstract
Background: A high complication rate of Q fever in pregnancy is described on the basis of a limited number of
cases. All pregnant women with proven Q fever regardless of clinical symptoms should therefore receive long-term
cotrimoxazole therapy. But cotrimoxazole as a folic acid antagonist may cause harm to the fetus. We therefore
investigated the Q fever outbreaks, Soest in 2003 and Jena in 2005, to determine the maternofetal consequences of
Coxiella burnetii infection contracted during pregnancy.
Methods: Different outbreak investigation strategies were employed at the two sides. Antibody screening was
performed with an indirect immunofluorescence test. Medical history and clinical data were obtained and
serological follow up performed at delivery. Available placental tissue, amniotic fluid and colostrum/milk were
further investigated by polymerase chain reaction and by culture.
Results: 11 pregnant women from Soest (screening rate: 49%) and 82 pregnant women from Jena (screening rate:
27%) participated in the outbreak investigation. 11 pregnant women with an acute C. burnetii infection were
diagnosed. Three women had symptomatic disease.
Three women, who were infected in the first trimester, were put on long-term therapy. The remaining women
received cotrimoxazole to a lesser extent (n=3), were treated with macrolides for three weeks (n=1) or after delivery
(n=1), were given no treatment at all (n=2) or received antibiotics ineffective for Q fever (n=1). One woman and her
foetus died of an underlying disease not related to Q fever. One woman delivered prematurely (35th week) and one
child was born with syndactyly. We found no obvious association between C. burnetii infection and negative
pregnancy outcome.
Conclusions: Our data do not support the general recommendation of long-term cotrimoxazole treatment for Q
fever infection in pregnancy. Pregnant women with symptomatic C. burnetii infections and with chronic Q fever
should be treated. The risk-benefit ratio of treatment in these patients, however, remains uncertain. If cotrimoxazole
is administered, folinic acid has to be added.
Background
Coxiella burnetii, an obligatory intracellular bacterium,
is the causative agent of Q fever, a zoonotic disease with
worldwide distribution. The clinical manifestations of
acute Q fever appear as atypical pneumonia, systemic fe-
brile illness or acute hepatitis. Roughly 50% of all infec-
tions with C. burnetii are asymptomatic [1].
Q fever is diagnosed by detection of antibodies against
two antigenic variations of the C. burnetii lipopolysac-
charide. IgM- and IgG-antibodies mainly directed
against the truncated form of lipopolysaccharide, called
Phase II (Ph2), appear in acute infection. In chronic Q
fever, high levels of IgG antibodies directed against
Phase I (Ph1), the complete lipopolysaccharide, are de-
tectable. Isolation of C. burnetii from medical specimen
is difficult as isolation is time-consuming and requires a
biosafety level 3 laboratory. Thus, detection by
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polymerase chain reaction (PCR) became a useful add-
itional tool in the past years [2,3].
Abortion material and birth products from ruminants
are the most commonly identified sources of human
infections. In these animals C. burnetii is associated with
abortions.
The pathogenic role of C. burnetii in pregnant women
is still uncertain. As of 2007, only 74 cases appeared in
publication. Of these some had serious complications
such us intrauterine fetal death (IUFD), maternofetal
death and spontaneous abortions. Based on these 74
cases long-term cotrimoxazole therapy of at least five
weeks duration has been recommended [4].
In Germany, Q fever outbreaks happen sporadically.
About 40 outbreaks in humans are documented from
1947 to 1999 [5].
Two significant outbreaks in Germany occured in
Soest in 2003 and in Jena in 2005.
The outbreak Soest was caused by a lambing sheep at
a farmers market that took place on May 3 and 4 in
2003 in a spa town near Soest. Approximately 3,000 visi-
tors from different parts of Germany visited the market.
A local hospital informed the health department of Soest
of an increase of atypical pneumonia 23 days later, May
26 2003. Altogether 299 cases related to this outbreak
were reported [6].
In Jena, from June 2nd to 18th 2005, 300 ewes with 35
lambing were grazing near densely populated area of
11,500 inhabitants. On the 27th of June, a practitioner
informed the health authorities of an increased number
of pneumonia in this district (Winzerla). The flock of
sheep was promptly identified as a potential source. Sus-
pected Q fever was confirmed few days later in animals
and humans [7]. Within a period of seven weeks
(13 June – 24 July), 331 cases were reported [8].
At both sites, Soest and Jena screening programs were
implemented to identify people with special risk for se-
vere disease; e.g., pregnancy.
We analyzed the obtained data to evaluate the mater-




Eleven pregnant women exposed at the farmers market
Soest took part in the screening program. This corre-
sponds to a screening rate of 49% (Figure 1).
82 pregnant women were included in the screening
program in Jena. 52 childbirths were registered in the
outbreak area during the 9 months following the expos-
ure. Out of these, 14 childbirths were covered by our
screening program, corresponding to a screening rate of
27% (Figure 2).
Women with C. burnetii infection in pregnancy
Altogether eleven pregnant women with an acute C.
burnetii infection were diagnosed, five in Soest in 2003
and six in Jena in 2005. Four of the five women in Soest,
have been briefly discussed [6]. The characteristics of
the 11 patients are presented in Table 1. Three women
had symptomatic disease, presenting with fever; one also
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Six women with Coxiella burnetii infection in pregnancy
Figure 2 Screening for pregnant women exposed at the
outbreak in Jena (*one woman was double tested).
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presented with pneumonia. All women seroconverted
during pregnancy.
No severe obstetrical complications; such as spontaneous
abortion, intrauterine fetal death or maternofetal death,
occurred due to Q fever. One woman, however, acquired
the infection in week six, recovered without treatment but
was soon put under cotrimoxazole treatment for prophy-
laxis. Because of pre-existing congestive heart failure with
the risk of decompensation during pregnancy she had to
undergo valvuloplasty two months later. Unfortunately she
developed postoperative complications and both she and
her foetus died. The maternal serum Ph1 IgG antibody level
was not elevated. The placenta did not show signs of
placentitis on microscopy.
All other women delivered full term (week 39-40, birth
weight 2970-4040 g) except one, who developed pneu-
monia at week 27 and delivered a baby (3250 g) at week
35. Other findings were oligohydramnion close to deliv-
ery (one case) and one child with a syndactyly of toe II-III
at birth. Her mother had received clarithromycin treat-
ment until delivery.
5 out of 7 placentas were investigated by PCR and cul-
ture and two by PCR alone. All were negative. The PCR
on colostrum/breast milk was positive in one out of five
samples investigated and breastfeeding was stopped. The
child had an uneventful follow up, whereas the mother
revealed a serological antibody pattern compatible with
chronic infection without echocardiographic signs or
symptoms of disease.
PCR performed on amniotic fluid was negative. A
serological profile compatible with chronic Q fever was
found in two women. No clinical or echocardiographic
signs of endocarditis were detected.
Antibiotic treatment was administered in nine cases
(Table 1). The recommended long-term cotrimoxazole
therapy was given to two women and one woman
received clarithromycin up to delivery. All three women
were infected in the first trimester. As noted above one
died of an underlying disease unrelated to Q fever. One
had additional infection with Toxoplasma gondii but
delivered a full term healthy baby. The third woman,
who was treated with clarithromycin gave birth to a
newborn with syndactyly of the right foot (dig II-III).
The other eight of eleven women were not treated
with the recommended cotrimoxazole therapy of at least
five weeks [4]. One woman was treated for Q fever
pneumonia with parenteral antibiotics (Erythromycin/
Clarithromycin) for three weeks. She prematurely deliv-
ered a 3250 g healthy baby in week 35. At the time of
birth she was healthy and all relevant tests were negative
for C. burnetii. All other women delivered full term
without complications.
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NOTE. * maternofetal death caused by an underlying disease other than Q fever (n=1), ** confirmed by Xray; 1 additional Toxoplasmose infection in pregnancy;
2toes II-III; 3 no C. burn-specific IgM-antibodies; 4 additional PCR on cord blood negative; RAD, respiratory adaption disorder; RDS, respiratory distress syndrome.
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Discussion
The estimated screening rate was very good in the out-
break Soest, although the visitors to the farmers market
came from various locations in Germany. Conversely,
the screening rate in Jena was only 27%. It is important
to point out, however, that the screening rate in Soest
was calculated using an estimated number of pregnant
women exposed. The low screening rate in Jena was
probably due to the fact that the information letter did
not contain sufficient details regarding the expected ben-
efits of screening and treatment. A recent study on
determinants for refusing participation on Q fever
screening in pregnancy found a response rate of 56%.
Approximately one quarter refused to participate be-
cause they had doubts about the side effects of the anti-
biotic treatment or were afraid of the consequences of
participation [9]. Another reason for the low screening
rate in Jena could have been the misconception that C.
burnetii infection contracted during pregnancy would al-
ways be symptomatic. This, and the frequent request to
screen all pregnant women with complications, could
have led to a selection of pregnancies with complications
or concomitant diseases. Our rate of 27% (3/11) of
symptomatic women compared to 10% (1/10) in a previ-
ous study corresponds to preselection [10].
However, we found no obvious association between C.
burnetii infection and negative pregnancy outcome, al-
though 73% (8/11) of the women did not receive the
recommended cotrimoxazole therapy of at least five
weeks [4]. The woman that was treated with clarithro-
mycin for the entire pregnancy gave birth to a newborn
with syndactyly. Syndactyly is a common fetal malforma-
tion (approximately 1 of 200 births) and several genetic
disorders can cause this disease [11]. Given the high in-
cidence of the disorder and the consequent treatment of
the mother, Q fever as causative agent appears to be un-
likely but cannot be ruled out.
The woman treated for Q fever pneumonia with
erythromycin/clarithromycin for three weeks, prema-
turely delivered although all relevant tests were negative
for C. burnetii. Given Germany’s premature birth rate of
7% this prematurity could be coincidental. All other
women delivered full term without complications.
In contrast to our findings a study, of 53 pregnant
women diagnosed with Q fever at the French National
Reference Centre for Rickettsioses revealed obstetric
complications in 81% of the 37 women without long-
term cotrimoxazole therapy [4]. But the study had a high
probability of a bias towards complicated cases.
Published evidence on the association between Q fever
and negative pregnancy outcomes is low. A systematic
review in 1990 identified only articles with level IV and
V evidence [12]. Of the 84 cases reported in the
literature to date, 53 were part of the large case series
noted above [4,13-16].
A recent large population based study in the Netherlands
investigated 1174 serum samples collected by an existing
national prenatal screening programme (at the 12th week of
pregnancy) and data from the Netherlands Perinatal Regis-
try on diagnosis and outcome. Out of these serum samples,
56 cases with acute C. burnetii infection during pregnancy
were identified and no association between C. burnetii in-
fection and preterm delivery, low birth weight or perinatal
mortality was observed [17]. In another comprehensive
study with 4588 participants, including 200 seropositive
women, they found an association between phase II anti-
body titre ≥ 1:32 and gestational age ≤ 36 weeks, current or
previous neonatal death, and higher parity. C. burnetii was
not identified by PCR or culture in the placentas investi-
gated [18].
The agent has been isolated in intact as well as nec-
rotic placentas with immaturity, abortion, maternofetal
death and stillbirth [4,14,16,19-23], but also from normal
placentas in undisturbed pregnancies [21,24-26]. This
suggests evidence against C. burnetii infection posing a
high risk to pregnancies. In our study all examined pla-
centas were negative for C. burnetii.
We found C. burnetii in the milk of one woman with
serological antibody pattern compatible to chronic infec-
tion but no clinical signs. Breastfeeding was stopped and
the child had an uneventful follow up. In other reports
C. burnetii was found repeatedly in human milk with
unclear implications for the breastfed child [24,27,28].
Whether pregnant women have an increased risk of
developing clinically apparent chronic Q fever remains
unresolved. In the largest case series published, 28 of 53
pregnant women developed a serological profile of
chronic Q fever. Three out of these 28 women devel-
oped an endocarditis, corresponding to 7% of all
included pregnant women [4]. A follow up study on
1569 acute Q fever cases revealed a development of
endocarditis in 12 (0.76%) cases [29]. This suggests a
higher risk for women infected during pregnancy com-
pared with the general population. In our study two
patients developed a serological profile of chronic Q
fever but none developed clinically apparent chronic
Q fever. Altogether our limited data cannot yet give con-
clusive answers to this question.
Several antibiotics such as cotrimoxazole, ciprofloxa-
cine, azithromycin, rifampicin, clarithromycin, doxycyc-
line, erythromycin and tifomycin have been given to
treat Q fever in pregnancy. The only study investigating
antibiotic treatment of Q fever in pregnancy found that
long-term cotrimoxazole therapy prevented obstetric
complications (p=0.009). However, patients (n=16) who
presented with obstetric complications at the time of
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diagnoses did not receive the long-term cotrimoxazole
therapy. Investigating only the 37 women with no com-
plications at the time of diagnoses, the efficacy of long-
term cotrimoxazole therapy to prevent IUFD was less
significant (0.047). Nevertheless, administration for all
pregnant women with proven Q fever was recom-
mended [4]. Even under cotrimoxazole therapy C. burne-
tii was detected in the placenta in some cases [4,16,25].
Cotrimoxazole is a folic acid antagonist that inhibits
deoxyribonucleic acid synthesis by interfering with the
production of folic acid. Exposure to it during pregnancy
appears to be associated with an increased risk of small-
for-gestational-age newborns, preterm births, cardiovas-
cular and neural tube defects [30-33]. Additional folinic
acid supplementation has a strong effect in the reduc-
tion of preterm birth and defects of the neural tube
[32,34].
Conclusions
We conclude that current knowledge about Q fever in
pregnancy is less than adequate. With the limited evi-
dence available to support treatment of pregnant women
with cotrimoxazole, and considering the risk of harming
the fetus, the recommendation of long-term cotrimoxa-
zole treatment for every pregnant woman with labora-
tory confirmed Q fever is questionable. On the other
hand pregnant women with symptomatic C. burnetii
infections and with chronic Q fever should be treated.
The risk-benefit ratio of treatment in these patients,
however, is also not clear. If cotrimoxazole is adminis-
tered, folinic acid has to be added.
Methods
Patients
Two different strategies were used to investigate the out-
breaks in Jena and Soest. Most of the visitors in Soest
came from various locations in Germany. Because of this
an appeal to screen every pregnant woman who had
attended the farmers market was published in the Jour-
nal of the German Medical Association. The county
Health authority used local press and publicized the
need to test all pregnant women. The appeal also offered
free antibody testing at the Q fever National Consulting
Laboratory (NCL). To evaluate the outbreak investiga-
tion strategies used in Soest, we first had to estimate the
total number of pregnant women who had visited the
market. Using the approximate number of visitors
(3000) and factoring in the known German birth-rate
(1/100/year), 0.75% is the prevalence of pregnant
women. This results in an estimate of 23 pregnant
women exposed in Soest (Figure 1).
The features of outbreak Jena enabled the local Health
Authority and the Robert Koch Institute to start a very
intense information policy rapidly. Within one week of
confirming the first human case of Q fever all gynaecol-
ogists and obstetricians in the town (n=18), the Jena
midwives birthing centre and the Department of the
University Hospital were notified by a letter which
recommended the screening of all women with compli-
cated pregnancies. In the second week the gynaecolo-
gists in the affected area (n=3) were encouraged by
telephone calls to screen all pregnant women with or
without complications. In the third week information
letters with the request to screen all pregnant women
were sent to all medical practices and also placed at the
front doors of all housing units in the affected area. The
NCL again offered free testing to exposed people. The ma-
ternity clinic of the University Hospital was designated as
centre for assisting infected women and the screening was
performed by the Health Authority Jena and at the
University Hospital Jena (Figure 2).
The registration office in Jena provided a list of
women living in the outbreak area and giving birth in
the nine month following the possible exposure. To
evaluate the coverage of our outbreak investigations we
compared this list to our list of screened women in the
well-defined outbreak area (Figure 2).
Medical history and clinical data were collected by the
responsible gynaecologists, paediatricians, the NCL and
the Department of Gastroenterology, Hepatology and In-
fectious Diseases of the University Hospital Jena. Pre-
term birth was defined as gestational age of less than 37
completed weeks. A serological follow up was performed
at delivery. Specimens of placental tissue and amniotic
fluid were obtained whenever possible. Additionally
breast milk or/and colostrum from the women exposed
in the outbreak in Soest were collected. All patients’
samples were taken as part of standard care. The study
was approved by the Ethical committee of the University
Hospital Jena (reference number 3439-04/12).
Serological testing
The serological diagnosis was done by a commercially
available indirect immunofluorescence antibody test
IFAT (BIOS/Focus, Cypress CA). For the IFAT all sera
were tested at dilutions 1:16, 1:64, 1:246 to 1:1024 in
phosphate buffered saline (PBS - BIOS, Germany, pH
7.8) and fluorescein isothiocyanate-labelled goat anti-
human IgG/IgM antibodies (BIOS, Germany) were used
as conjugate. The examination was done by fluorescent
microscopy.
An acute infection with C. burnetii was defined as the
presence of IgM antibodies against Ph2 antigen or/and a
seroconversion. Raised IgG antibodies against Ph1 anti-
gen of more than 1:800 were determined to be a sero-
logical profile of a chronic infection.
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Polymerase chain reaction
Two different PCR protocols were used. Both target the
transposase of insertion sequence element IS 1111.
All placentas, amniotic fluids and colostrum/milk from
patients exposed in the Soest outbreak were investigated
using primer CoxP4 (5`TTAAGGTGGGCTGCGTGGT
GATGG) and CoxM9 (5`GCTTCGTCCCGGTTCAACA
ATTCG) according to the conventional PCR by Schrader
[35]. It amplifies a 448-bp fragment of genomic DNA. The
temperature regime was modified as touchdown PCR with
five cycles of a declining annealing temperature (75 to 67°C
in steps of 2°C). The DNA was extracted using the
Puregene Extraction Kit (Biozym) as described by the
manufacturer.
All placentas collected during the outbreak in Jena
were investigated by a nested PCR according to Fenollar
[2]. For the first amplification cycle the primers IS111 F1
(5`TACTGGGTGTTGATATTGC-3`) and IS111 R1 (5`-
CCGTTTCATCCGCGGTG-3`), which target a 485-bp
fragment were used. PCR was first carried out using the
following profile: 95°C for 3 min, 95°C for 30 sec, 52°C
for 30 sec, 72°C for 1 min (40 cycles), 72°C for 4 min.
Reamplification was performed with the IS111 F2 (5`-
GTAAAGTGATCTACACGA-3`) and IS 111 R2 (5`-
TTAACAGCGCTTGAACGT-3`) primers, which target
a 260-bp fragment: 95°C for 3 min, 95°C for 30 sec, 52°C
for 30 sec and 72°C for 30 sec (30 cycles), 72°C for
4 min. The PCR-samples were analysed using gel
electrophoresis.
Culture
The placentas collected during the Soest outbreak were
examined by cell culture using Buffalo Green Monkey
(BGM) cells and a serum free-medium (UltraCulture, Bio
Whittaker Europe, Verviers, Belgium) without antibiotics.
The samples were homogenised using sterile sand and
cell culture medium, the supernatants filtered through
0.2 μm syringe filters (Minisart, Sartorius, Hannover,
Germany) and used as inocula. Cell cultures were incu-
bated at 35°C and 5% CO2 and investigated weekly for
seven weeks using phase contrast microscopy [36].
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